Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Titel:
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Auteur:
Feagan, Brian G Sandborn, William J D'Haens, Geert Panés, Julián Kaser, Arthur Ferrante, Marc Louis, Edouard Franchimont, Denis Dewit, Olivier Seidler, Ursula Kim, Kyung-Jo Neurath, Markus F Schreiber, Stefan Scholl, Paul Pamulapati, Chandrasena Lalovic, Bojan Visvanathan, Sudha Padula, Steven J Herichova, Ivona Soaita, Adina Hall, David B Böcher, Wulf O